albuterol has been researched along with Cardiovascular Diseases in 19 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Excerpt | Relevance | Reference |
---|---|---|
"COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease." | 2.76 | Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. ( Cicale, MJ; Cockcroft, JR; Coxson, HO; Crater, GD; Dransfield, MT; Emmett, AH; Martinez, FJ; Rubin, DB; Sharma, SS; Townsend, RR, 2011) |
"Previous studies have suggested that long-term use of beta agonists to treat chronic obstructive pulmonary disease (COPD) may increase the risk of cardiovascular adverse events." | 2.75 | Cardiovascular events in patients with COPD: TORCH study results. ( Anderson, JA; Calverley, PM; Celli, B; Crim, C; Ferguson, GT; Jenkins, C; Jones, PW; Vestbo, J; Willits, LR; Yates, JC, 2010) |
"Treatment with salmeterol, 50 micro g bid, showed no increased risk of cardiovascular adverse events (AEs) compared with placebo (relative risk, 1." | 2.71 | Cardiovascular safety of salmeterol in COPD. ( Darken, P; Ferguson, GT; Fischer, T; Funck-Brentano, C; Reisner, C, 2003) |
"Although large surveys have documented the favourable safety profile of beta(2)-adrenoceptor agonists (beta(2)-agonists) and, above all, that of the long-acting agents, the presence in the literature of reports of adverse cardiovascular events in patients with obstructive airway disease must induce physicians to consider this eventuality." | 2.43 | Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. ( Cazzola, M; Donner, CF; Matera, MG, 2005) |
" Adverse events (AEs) were analysed overall and according to Anti-Platelet Trialists' Collaboration (APTC) criteria and baseline cardiovascular risk factors." | 1.37 | Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. ( Chung, KF; Felser, JM; Hu, H; Rueegg, P; Worth, H, 2011) |
"To compare the risk of total mortality and certain respiratory and cardiac adverse events among users of the two types of recommended long-acting bronchodilators, we conducted a cohort study." | 1.34 | Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. ( Jara, M; Kesten, S; Lanes, SF; May, C; Wentworth, C, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.26) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 10 (52.63) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Moore, LE | 2 |
Kapoor, K | 1 |
Byers, BW | 2 |
Brotto, AR | 1 |
Ghods-Esfahani, D | 1 |
Henry, SL | 1 |
St James, RB | 1 |
Stickland, MK | 2 |
Kelly, A | 1 |
Kennedy, A | 1 |
John, BM | 1 |
Duane, B | 1 |
Lemanowicz, J | 1 |
Little, J | 1 |
Jones, A | 1 |
Vennelle, M | 1 |
Connell, M | 1 |
McKillop, G | 1 |
Newby, DE | 1 |
Douglas, NJ | 1 |
Riha, RL | 1 |
Edgell, H | 1 |
Chung, C | 1 |
Calaghan, S | 1 |
Kozera, L | 1 |
White, E | 1 |
Richie, RC | 1 |
Płusa, T | 1 |
Calverley, PM | 1 |
Anderson, JA | 1 |
Celli, B | 1 |
Ferguson, GT | 2 |
Jenkins, C | 1 |
Jones, PW | 1 |
Crim, C | 1 |
Willits, LR | 1 |
Yates, JC | 1 |
Vestbo, J | 1 |
Worth, H | 1 |
Chung, KF | 1 |
Felser, JM | 1 |
Hu, H | 1 |
Rueegg, P | 1 |
Dransfield, MT | 1 |
Cockcroft, JR | 1 |
Townsend, RR | 1 |
Coxson, HO | 1 |
Sharma, SS | 1 |
Rubin, DB | 1 |
Emmett, AH | 1 |
Cicale, MJ | 1 |
Crater, GD | 1 |
Martinez, FJ | 1 |
Oba, Y | 1 |
Ruel, G | 1 |
Lapointe, A | 1 |
Pomerleau, S | 1 |
Couture, P | 1 |
Lemieux, S | 1 |
Lamarche, B | 1 |
Couillard, C | 1 |
Funck-Brentano, C | 1 |
Fischer, T | 1 |
Darken, P | 1 |
Reisner, C | 1 |
Cazzola, M | 1 |
Matera, MG | 1 |
Donner, CF | 1 |
Jara, M | 1 |
Lanes, SF | 1 |
Wentworth, C | 1 |
May, C | 1 |
Kesten, S | 1 |
Staudinger, HW | 1 |
Haas, JF | 1 |
Colin, P | 1 |
Berdeaux, A | 1 |
Lipworth, BJ | 1 |
Burggraaf, J | 1 |
Westendorp, RG | 1 |
in't Veen, JC | 1 |
Schoemaker, RC | 1 |
Sterk, PJ | 1 |
Cohen, AF | 1 |
Blauw, GJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered[NCT00268216] | Phase 3 | 6,228 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) i[NCT00463567] | Phase 2/Phase 3 | 2,059 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol ([NCT00567996] | Phase 3 | 1,002 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary D[NCT00393458] | Phase 3 | 1,732 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)[NCT00857766] | Phase 4 | 249 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"A Chronic Obstructive Pulmonary Disease (COPD) day of poor control was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of days of poor control as well as FEV1 reversibility components as covariates." (NCT00463567)
Timeframe: up to 26 weeks
Intervention | Percentage of days (Least Squares Mean) |
---|---|
Indacaterol 150 µg (Continued Into Stage 2) | 31.5 |
Indacaterol 300 µg (Continued Into Stage 2) | 30.8 |
Tiotropium (Continued Into Stage 2) | 31.0 |
Placebo (Continued Into Stage 2) | 34.0 |
"Interim Analysis: Stage 1.~Spirometry was conducted according to internationally accepted standards. Standardized with respect to time (AUC 1h-4h) for FEV1 measurements taken from 1 hour to 4 hour post morning dose on Day 14. Standardized FEV1 AUC was calculated by the trapezoidal rule. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates." (NCT00463567)
Timeframe: Day 14, After 2 Weeks of treatment in Stage 1
Intervention | Liters (Least Squares Mean) |
---|---|
Indacaterol 150 µg | 1.53 |
Indacaterol 300 µg | 1.58 |
Tiotropium 18 µg | 1.49 |
Placebo | 1.30 |
Indacaterol 75 µg | 1.50 |
Indacaterol 600 µg | 1.53 |
Formoterol 12 µg | 1.52 |
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates. (NCT00463567)
Timeframe: after 12 weeks of treatment
Intervention | Liters (Least Squares Mean) |
---|---|
Indacaterol 150 µg (Continued Into Stage 2) | 1.46 |
Indacaterol 300 µg (Continued Into Stage 2) | 1.46 |
Tiotropium 18 µg (Continued Into Stage 2) | 1.42 |
Placebo (Continued Into Stage 2) | 1.28 |
"Interim Analysis: Stage 1.~Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates." (NCT00463567)
Timeframe: Day 15, After 2 Weeks of treatment in Stage 1
Intervention | Liters (Least Squares Mean) |
---|---|
Indacaterol 150 µg | 1.49 |
Indacaterol 300 µg | 1.52 |
Tiotropium 18 µg | 1.45 |
Placebo | 1.31 |
Indacaterol 75 µg | 1.46 |
Indacaterol 600 µg | 1.51 |
Formoterol 12 µg | 1.42 |
"Participants rated their symptoms on a scale of 0=none to 3=severe. A Chronic Obstructive Pulmonary Disease (COPD) day of poor control was defined as any day in the participants diary with a score >=2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). The mixed model used baseline percentage of days of poor control, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates." (NCT00567996)
Timeframe: Up to 26 weeks
Intervention | Percentage of days (Least Squares Mean) |
---|---|
Indacaterol 150 μg | 34.1 |
Salmeterol 50 μg | 34.1 |
Placebo | 38.1 |
SGRQ is a health related quality of life questionnaire consisting of 76 items in three sections: symptoms, activity and impacts. The total score is 0 to 100 with a higher score indicating poorer health status. The mixed model used baseline SGRQ total score, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates. (NCT00567996)
Timeframe: Week 12
Intervention | Score on a scale (Least Squares Mean) |
---|---|
Indacaterol 150 μg | 36.4 |
Salmeterol 50 μg | 38.5 |
Placebo | 42.6 |
Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates. (NCT00567996)
Timeframe: Week 12
Intervention | Liters (Least Squares Mean) |
---|---|
Indacaterol 150 μg | 1.45 |
Salmeterol 50 μg | 1.39 |
Placebo | 1.28 |
Percentage of days of poor control was defined as the number of days in the patient diary with a score ≥ 2 (scale of 0-3, a higher number means more severe symptoms) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness) over 52 weeks divided by the number of evaluable days (days with ≥ 2 symptoms with scores). The analysis included baseline percentage of days of poor control, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates. (NCT00393458)
Timeframe: Baseline to end of study (Week 52)
Intervention | Percentage of days (Least Squares Mean) |
---|---|
Indacaterol 300 μg Plus Placebo to Formoterol | 33.6 |
Indacaterol 600 μg Plus Placebo to Formoterol | 30.0 |
Formoterol 12 μg Plus Placebo to Indacaterol | 33.5 |
Placebo to Indacaterol Plus Placebo to Formoterol | 38.3 |
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates. (NCT00393458)
Timeframe: Week 12 + 1 day, Day 85
Intervention | Liters (Least Squares Mean) |
---|---|
Indacaterol 300 μg Plus Placebo to Formoterol | 1.48 |
Indacaterol 600 μg Plus Placebo to Formoterol | 1.48 |
Formoterol 12 μg Plus Placebo to Indacaterol | 1.38 |
Placebo to Indacaterol Plus Placebo to Formoterol | 1.31 |
The 12-week Endpoint is defined as the last scheduled measurement of PWV during the 12-week double-blind treatment period (from Visits 3-5; Weeks 4, 8, and 12, respectively), and Baseline is defined as the PWV measure from Visit 2 (Randomization). Change from Baseline was calculated as the Endpoint value minus the Baseline Value. PWV is used as a measure of arterial stiffness, which is a measure of the cushioning functioning of major vessels like the aorta. The velocity of the PW along an artery is dependent on the stiffness of that artery. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)
Intervention | meters per second (m/s) (Mean) | ||
---|---|---|---|
Baseline, n=118, 122 | 12-Week Endpoint, n=113, 110 | Change from Baseline | |
FSC DISKUS 250/50 mcg | 10.06 | 9.83 | -0.24 |
Matching Placebo | 9.87 | 9.95 | 0.13 |
AIx is a surrogate measure of peripheral (not aortic) arterial resistance and is measured by analysis of the pulse wave at the radial artery. AIx = ([delta P/Pulse Pressure] x 100); delta P is defined by a notch near the peak of the pulse wave. Change from Baseline was calculated as the Endpoint value minus the Baseline Value. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)
Intervention | % of total height of peak pulse pressure (Mean) | ||
---|---|---|---|
Baseline, n=121, 122 | 12-Week Endpoint, n=114, 111 | Change from Baseline | |
FSC DISKUS 250/50 mcg | 27.9 | 27.2 | -0.7 |
Matching Placebo | 27.8 | 27.6 | -0.4 |
FEV1 is a measure of air flow via spirometry. Change from Baseline was calculated as the Endpoint value minus the Baseline Value. (NCT00857766)
Timeframe: Baseline and the 12-Week Endpoint (up to Week 12)
Intervention | milliliters (Mean) | ||
---|---|---|---|
Baseline, n=123, 125 | 12-Week Endpoint, n=105, 102 | Change from Baseline | |
FSC DISKUS 250/50 mcg | 1444 | 1588 | 136 |
Matching Placebo | 1480 | 1500 | -3 |
1 review available for albuterol and Cardiovascular Diseases
Article | Year |
---|---|
Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol | 2005 |
6 trials available for albuterol and Cardiovascular Diseases
Article | Year |
---|---|
The effect of continuous positive airway pressure therapy on arterial stiffness and endothelial function in obstructive sleep apnea: a randomized controlled trial in patients without cardiovascular disease.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Aorta; Blood Flow Velocity; Cardiovascular Di | 2013 |
Cardiovascular events in patients with COPD: TORCH study results.
Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Albuterol; Androstadienes; Bronchodilator | 2010 |
Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
Topics: Albuterol; Androstadienes; Arteries; Blood Flow Velocity; Cardiovascular Diseases; Double-Blind Meth | 2011 |
Evidence that cranberry juice may improve augmentation index in overweight men.
Topics: Adult; Albuterol; Beverages; Blood Pressure; Cardiovascular Diseases; Cardiovascular Physiological P | 2013 |
Cardiovascular safety of salmeterol in COPD.
Topics: Adrenergic beta-Agonists; Aged; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cardiovas | 2003 |
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Analysis of Variance; Asthma | 2001 |
12 other studies available for albuterol and Cardiovascular Diseases
Article | Year |
---|---|
Acute effects of salbutamol on systemic vascular function in people with asthma.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Blood Pre | 2019 |
A comparison of heart rate changes associated with levalbuterol and racemic albuterol in pediatric cardiology patients.
Topics: Adolescent; Albuterol; Bronchoconstriction; Bronchodilator Agents; Cardiovascular Diseases; Child; C | 2013 |
Short-term cardiovascular and autonomic effects of inhaled salbutamol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Arterial Pressure | 2016 |
Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte.
Topics: Actin Cytoskeleton; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animal | 2008 |
Assessing mortality risk in COPD.
Topics: Actuarial Analysis; Albuterol; Androstadienes; Body Mass Index; Bronchial Hyperreactivity; Bronchodi | 2008 |
[Agonists of beta2 adrenergic receptor in the therapy of obstructive diseases].
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Arrhythmias, Cardiac; Card | 2010 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanol | 2011 |
Tiotropium versus salmeterol in COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; C | 2011 |
Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database.
Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Cardio | 2007 |
Extrapulmonary effects of fenoterol compared to salbutamol in asthmatics.
Topics: Albuterol; Asthma; Cardiovascular Diseases; Drug Administration Schedule; Fenoterol; Humans | 1993 |
[Beta-adrenergic agonists (adrenaline, dopamine, dobutamine, salbutamol), beta-blockers. Principles and regulations of use].
Topics: Adrenergic beta-Agonists; Albuterol; Cardiovascular Diseases; Dobutamine; Dopamine; Epinephrine; Hum | 2001 |
Revisiting interactions between hypoxaemia and beta2 agonists in asthma.
Topics: Adrenergic beta-Agonists; Albuterol; Asthma; Cardiovascular Diseases; Dose-Response Relationship, Dr | 2001 |